Showing results (181-190 of 203) with videos related to

Sort By:
Pageof 21
ACS Applied Materials & Interfaces|December 8, 2025
Highly Efficient Surface Passivation with Cation-Exchanged Quasi-2D Perovskites for High-Sensitivity and Low-Dose X-ray Flat-Panel ImagingZhiyuan Wang, Liangrui Yu, Xin He, et al.
European Urology Oncology|October 17, 2025
Endoscopic Thulium Laser Ablation with Disitamab Vedotin and Immunotherapy in High-risk Upper Tract Urothelial Carcinoma: A Prospective Pilot Study of a Novel Kidney-sparing StrategyJianjun Ye, Zeyu Chen, Xinyang Liao, et al.
Cancer Science|October 13, 2020
Tislelizumab in Asian patients with previously treated locally advanced or metastatic urothelial carcinomaDingwei Ye, Jiyan Liu, Aiping Zhou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2020
Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial CarcinomaXinan Sheng, Xieqiao Yan, Lin Wang, et al.
Vaccine|April 19, 2011
Antitumour immunity mediated by mannan-modified adenovirus vectors expressing VE-cadherinZhiwei Zhao, Yaqin Yao, Zhenyu Ding, et al.
The Prostate|May 24, 2021
Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patientsSha Zhu, Junru Chen, Yuchao Ni, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2023
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical TrialsXinan Sheng, Lin Wang, Zhisong He, et al.
Journal of the National Cancer Center|July 22, 2024
Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerHuizi Lei, Yun Ling, Pei Yuan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2021
Safety, Efficacy, and Biomarker Analysis of Toripalimab in Patients with Previously Treated Advanced Urothelial Carcinoma: Results from a Multicenter Phase II Trial POLARIS-03Xinan Sheng, Haige Chen, Bin Hu, et al.
The Prostate|July 12, 2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapyJinge Zhao, Mengni Zhang, Jiandong Liu, et al.
Pageof 21